Ten-Year Follow-up Clinical Outcomes and the Role of Adjuvant Chemotherapy in HER2-Positive Patients with Microinvasive Breast Cancer.

Cancer Res Treat · 2026 · PMC12800945 · PMID 40045569

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, the NSABP B-43 compared adjuvant trastuzumab versus placebo after lumpectomy for patients with HER2-positive DCIS and did not report a significant reduction in the IBTR rates, though it showed a trend toward numerical improvement in non-invasive IBTR rates [ 27 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.